IFT20 Confers Paclitaxel Resistance by Triggering β-arrestin-1 to Modulate ASK1 Signaling in Breast Cancer

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Paclitaxel chemotherapy is a primary treatment for breast cancer.
• Chemotherapy resistance is a significant challenge, hindering treatment efficacy.
• Understanding chemoresistance mechanisms is crucial for improving patient outcomes.

Purpose of the Study:

• To investigate the role of intraflagellar transport 20 (IFT20) in paclitaxel resistance in breast cancer.
• To elucidate the molecular mechanisms by which IFT20 influences chemoresistance.
• To identify IFT20 as a potential biomarker for predicting response to paclitaxel therapy.

Main Methods:

• Correlation analysis of IFT20 expression with relapse-free survival in breast cancer patients.
• In vitro studies assessing the effect of IFT20 expression levels on paclitaxel-induced apoptosis.
• Mechanistic studies involving protein-protein interactions and signaling pathway analysis (ASK1, JNK).

Main Results:

• High IFT20 expression is associated with shorter relapse-free survival in patients receiving paclitaxel.
• Elevated IFT20 levels confer resistance to paclitaxel-induced cell death.
• IFT20 knockdown sensitizes breast cancer cells to paclitaxel.
• IFT20 promotes paclitaxel resistance by facilitating ASK1 ubiquitination and degradation, thereby attenuating ASK1/JNK signaling.

Conclusions:

• IFT20 drives paclitaxel resistance in breast cancer by modulating the ASK1 signaling pathway.
• IFT20 represents a potential molecular biomarker for predicting patient response to paclitaxel-based chemotherapy.
• Targeting IFT20 may offer a novel therapeutic strategy to overcome paclitaxel resistance.